BURLINGAME, Calif. – June 3, 2021 – Preferred Medicine Inc., a joint venture between Preferred Networks Inc. (PFN) and Mitsui & Co., Ltd. (Mitsui), announced today that a joint research on machine learning-based cancer detections with circulating microRNA (miRNA) profiles in the blood will be presented at the 2021 annual meeting of American Society of Clinical Oncology (ASCO), to be held on June 4 – 8, 2021. The joint research was conducted in the U.S. by Preferred Networks America, Inc., Preferred Medicine and National Cancer Center Japan.

(Read more on Preferred Medicine’s website)